DYADIC INTL INC. DL-,001

Dyadic says it has evolved from an R&D company into a commercial provider and is now pursuing an asset-light business model with licensing, profit-sharing, direct sales and distribution partnerships. The short-term goal is to achieve positive cash flow through recurring revenues, with partnerships with Proliant, Inzymes ApS, Fermbox Bio and Integrated Biotherapeutics being central. Management does not provide an annual revenue forecast but emphasizes growing commercial revenues in the life sciences, food & nutrition and biomanufacturing segments. The stock closed at $0.66 (-4.47%), near its 52-week low. » More on de.investing.com

Dyadic announces the closing of binding agreements for a registered direct offering and a concurrent private placement with expected gross proceeds of about $2.9 million. The company is selling 3,625,000 common shares at $0.795 per share and issuing warrants to purchase an additional 3,625,000 shares at an exercise price of $0.84; the warrants are priced at $0.005 each. Aegis Capital is acting as sole placement agent; net proceeds will be used for general corporate purposes and as working capital. » More on de.investing.com

Dyadic International reported second‑quarter revenue of $961,000, beating consensus estimates, but posted a larger net loss of $0.06 per share versus an expected $0.04. The stock fell 16.19% to $0.88 after the release, as investors weighed the losses, funding needs and a note on going concern more heavily than the revenue beat. The company has about $4.8 million in cash and expects irregular product revenues in the third quarter, while emphasizing a shift from platform development to a more commercial business model. » More on de.investing.com